JP2008535871A - 器官又は組織における線維症を処置するための医薬の製造における５−メチル−１−（置換されたフェニル）−２−（１ｈ）−ピリドン - Google Patents

器官又は組織における線維症を処置するための医薬の製造における５−メチル−１−（置換されたフェニル）−２−（１ｈ）−ピリドン Download PDF

Info

Publication number
JP2008535871A
JP2008535871A JP2008505716A JP2008505716A JP2008535871A JP 2008535871 A JP2008535871 A JP 2008535871A JP 2008505716 A JP2008505716 A JP 2008505716A JP 2008505716 A JP2008505716 A JP 2008505716A JP 2008535871 A JP2008535871 A JP 2008535871A
Authority
JP
Japan
Prior art keywords
methyl
pyridone
fibrosis
compound
akf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535871A5 (enExample
Inventor
立▲じあん▼ 陶
高云 胡
エリック シ，ユエニアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiangya Hospital Central South University
Original Assignee
Xiangya Hospital Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiangya Hospital Central South University filed Critical Xiangya Hospital Central South University
Publication of JP2008535871A publication Critical patent/JP2008535871A/ja
Publication of JP2008535871A5 publication Critical patent/JP2008535871A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008505716A 2005-04-13 2006-04-11 器官又は組織における線維症を処置するための医薬の製造における５−メチル−１−（置換されたフェニル）−２−（１ｈ）−ピリドン Pending JP2008535871A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2005100314457A CN1846699A (zh) 2005-04-13 2005-04-13 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
PCT/CN2006/000651 WO2006108354A1 (fr) 2005-04-13 2006-04-11 5-méthyl-2-(1h)-pyridone substituée en 1 par un groupement phényle dans la fabrication de médicaments pour le traitement de la fibrose d'organes ou de tissus

Publications (2)

Publication Number Publication Date
JP2008535871A true JP2008535871A (ja) 2008-09-04
JP2008535871A5 JP2008535871A5 (enExample) 2009-06-18

Family

ID=37076581

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505716A Pending JP2008535871A (ja) 2005-04-13 2006-04-11 器官又は組織における線維症を処置するための医薬の製造における５−メチル−１−（置換されたフェニル）−２−（１ｈ）−ピリドン

Country Status (10)

Country Link
US (3) US20090005424A9 (enExample)
EP (1) EP1878428A4 (enExample)
JP (1) JP2008535871A (enExample)
KR (1) KR20080018857A (enExample)
CN (2) CN1846699A (enExample)
AU (1) AU2006233433A1 (enExample)
CA (1) CA2603763A1 (enExample)
RU (1) RU2007141892A (enExample)
TW (1) TW200808315A (enExample)
WO (1) WO2006108354A1 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8725326B2 (en) 2006-03-20 2014-05-13 General Electric Company System and method for predicting a vehicle route using a route network database
US8751073B2 (en) 2006-03-20 2014-06-10 General Electric Company Method and apparatus for optimizing a train trip using signal information
US8903573B2 (en) 2006-03-20 2014-12-02 General Electric Company Method and computer software code for determining a mission plan for a powered system when a desired mission parameter appears unobtainable
US8924049B2 (en) 2003-01-06 2014-12-30 General Electric Company System and method for controlling movement of vehicles
US9156477B2 (en) 2006-03-20 2015-10-13 General Electric Company Control system and method for remotely isolating powered units in a vehicle system
JP2016540800A (ja) * 2013-12-19 2016-12-28 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体およびその医薬品への応用
US9669851B2 (en) 2012-11-21 2017-06-06 General Electric Company Route examination system and method
US9733625B2 (en) 2006-03-20 2017-08-15 General Electric Company Trip optimization system and method for a train
US9834237B2 (en) 2012-11-21 2017-12-05 General Electric Company Route examining system and method
US10308265B2 (en) 2006-03-20 2019-06-04 Ge Global Sourcing Llc Vehicle control system and method
US10569792B2 (en) 2006-03-20 2020-02-25 General Electric Company Vehicle control system and method

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825133B2 (en) 2003-11-14 2010-11-02 Shanghai Genomics, Inc. Derivatives of pyridone and the use of them
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
US9689681B2 (en) 2014-08-12 2017-06-27 General Electric Company System and method for vehicle operation
WO2009039773A1 (fr) * 2007-09-19 2009-04-02 Central South University Nouvelle utilisation thérapeutique d'une aryl-2(1h)-pyridone substituée en position 1
CN101235013A (zh) * 2008-03-10 2008-08-06 广东东阳光药业有限公司 结晶型1-（3-氟苯基）-5-甲基-2-（1h）吡啶酮、其制备方法、及其组合物和应用
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
WO2010045871A1 (en) * 2008-10-21 2010-04-29 Dieretech Investment Limited Composition and method for treating proteinuria
US7566729B1 (en) 2008-11-10 2009-07-28 Intermune, Inc. Modifying pirfenidone treatment for patients with atypical liver function
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8016980B2 (en) 2008-11-25 2011-09-13 Dixie Consumer Products Llc Paper products
CN101921225B (zh) * 2009-06-11 2013-04-03 北京凯得尔森生物技术有限公司 吡啡尼酮类化合物、其制备方法和应用
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US8084475B2 (en) 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
CA2819967C (en) 2012-08-31 2016-03-22 Intermune, Inc. Use of pirfenidone concomitantly with ciprofloxacin
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9682716B2 (en) 2012-11-21 2017-06-20 General Electric Company Route examining system and method
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
BR112016020987B1 (pt) 2014-03-12 2023-11-14 Western Sydney Local Health District Método de identificação de receptores de aloenxerto renal e método de seleção de receptor do aloenxerto renal
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
ES2850281T3 (es) 2014-06-26 2021-08-26 Icahn School Med Mount Sinai Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión
WO2016044153A1 (en) * 2014-09-18 2016-03-24 Rush University Medical Center Methods for preventing or treating osteoarthritis
DE102015217418A1 (de) 2015-09-11 2017-03-16 Mühlbauer Technology Gmbh Radikalisch polymerisierbares Dentalmaterial
EP3308765B1 (de) 2016-10-17 2022-07-13 Mühlbauer Technology GmbH Radikalisch polymerisierbare verbindung
WO2019011163A1 (en) * 2017-07-14 2019-01-17 Sunshine Lake Pharma Co., Ltd. PROCESS FOR THE PREPARATION OF A PYRIMIDONE COMPOUND
JP7464279B2 (ja) 2018-04-16 2024-04-09 アイカーン スクール オブ メディスン アット マウント シナイ レシピエント血液における移植前トランスクリプトームシグネチャーを使用した急性拒絶反応および腎臓同種異系移植喪失の予測のための方法およびキット
CN113456636A (zh) * 2021-07-09 2021-10-01 中南大学 一种氟非尼酮在制备急性肝损伤药物中的应用
CN113274389B (zh) * 2021-07-09 2022-11-08 中南大学 氟非尼酮在制备治疗急性肺损伤药物中的应用
CN114716365B (zh) * 2022-01-04 2024-03-01 大连理工大学 一类n-取代苯基-2-吡啶酮化合物或其可药用盐在治疗肺纤维化中的应用
WO2024235145A1 (zh) * 2023-05-12 2024-11-21 大连理工大学 一类n-取代苯基-2-吡啶酮及内过氧化物的制备和应用
CN121695138A (zh) * 2023-10-30 2026-03-20 大连理工大学 一类n-取代苯基-2-吡啶酮化合物在治疗癌症中的应用
CN120053452B (zh) * 2023-11-30 2025-12-05 长沙晶易医药科技股份有限公司 一种2,4-二取代-5-氟嘧啶衍生物的新用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000051467A (ja) * 1998-08-07 2000-02-22 Takao:Kk 弾球遊技機
EP1138329A2 (en) * 1989-02-15 2001-10-04 Yamauchi, Shitotomo Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
CA1049411A (en) 1972-12-18 1979-02-27 Affiliated Medical Research N-substituted pyridone and general method for preparing pyridones
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
CN2114190U (zh) 1992-01-09 1992-08-26 王刚 恒流一体化集成电源器件
US5716623A (en) * 1994-12-07 1998-02-10 Immunex Corporation Isolated Herpesvirus saimiri proteins that bind MHC Class II molecules
CN1218942C (zh) * 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
CN1846699A (zh) * 2005-04-13 2006-10-18 中南大学湘雅医院 1－(取代苯基)－5－甲基－2－(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1138329A2 (en) * 1989-02-15 2001-10-04 Yamauchi, Shitotomo Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions
JP2000051467A (ja) * 1998-08-07 2000-02-22 Takao:Kk 弾球遊技機

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012014338; Ｊ．Ｃｅｎｔ．　Ｓｏｕｔｈ　Ｕｎｉ．　（Ｍｅｄ．Ｓｃｉ．） Ｖｏｌ．２９，Ｎｏ．２, 2004 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8924049B2 (en) 2003-01-06 2014-12-30 General Electric Company System and method for controlling movement of vehicles
US8725326B2 (en) 2006-03-20 2014-05-13 General Electric Company System and method for predicting a vehicle route using a route network database
US8751073B2 (en) 2006-03-20 2014-06-10 General Electric Company Method and apparatus for optimizing a train trip using signal information
US8903573B2 (en) 2006-03-20 2014-12-02 General Electric Company Method and computer software code for determining a mission plan for a powered system when a desired mission parameter appears unobtainable
US9156477B2 (en) 2006-03-20 2015-10-13 General Electric Company Control system and method for remotely isolating powered units in a vehicle system
US9733625B2 (en) 2006-03-20 2017-08-15 General Electric Company Trip optimization system and method for a train
US10308265B2 (en) 2006-03-20 2019-06-04 Ge Global Sourcing Llc Vehicle control system and method
US10569792B2 (en) 2006-03-20 2020-02-25 General Electric Company Vehicle control system and method
US9669851B2 (en) 2012-11-21 2017-06-06 General Electric Company Route examination system and method
US9834237B2 (en) 2012-11-21 2017-12-05 General Electric Company Route examining system and method
JP2016540800A (ja) * 2013-12-19 2016-12-28 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体およびその医薬品への応用

Also Published As

Publication number Publication date
US20090005424A9 (en) 2009-01-01
US20090258911A1 (en) 2009-10-15
EP1878428A1 (en) 2008-01-16
EP1878428A4 (en) 2008-09-03
CA2603763A1 (en) 2006-10-19
CN1953749A (zh) 2007-04-25
US20080319027A1 (en) 2008-12-25
CN1953749B (zh) 2010-04-14
KR20080018857A (ko) 2008-02-28
AU2006233433A1 (en) 2006-10-19
US20070203203A1 (en) 2007-08-30
WO2006108354A1 (fr) 2006-10-19
RU2007141892A (ru) 2009-05-20
CN1846699A (zh) 2006-10-18
TW200808315A (en) 2008-02-16

Similar Documents

Publication Publication Date Title
EP1878428A1 (en) 1-(substituted phenyl)-5- methyl- 2 - (1h) pyridone in the manufacture of medicaments for treating fibrosis in organs or tissues
RU2557243C2 (ru) Фармацевтическая композиция, содержащая индольное соединение
EP1364659A1 (en) Remedies for urinary diseases comprising lpa receptor controlling agents
JP7457360B2 (ja) 線維症の処置
US20250017934A1 (en) New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases
Shao et al. Stachydrine ameliorates the progression of intervertebral disc degeneration via the PI3K/Akt/NF-κB signaling pathway: in vitro and in vivo studies
AU2025205402A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
TWI885807B (zh) 一類具有萘胺結構的小分子化合物的用途
TW201026684A (en) Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy
KR102676631B1 (ko) 과민성 방광의 예방 또는 치료용 약학적 조성물
JPH07500811A (ja) アミノ置換ピリミジン、その誘導体及びその使用方法
TWI769325B (zh) 糖尿病性腎病之預防藥及／或治療藥
JP2004534760A (ja) 腎線維症の治療
JP2008514636A (ja) サイトカイン活性の低分子モジュレーター
CN106466318A (zh) 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用
WO2017216579A1 (en) Autophagy inducer compounds
EP4252751B1 (en) Pharmaceutical composition for preventing or treating wound or scar, comprising benzbromarone
KR101199730B1 (ko) 병리학적 맥락막 혈관신생과 관련된 질환을 치료하기 위한1,2,3-치환된 인돌리진 유도체의 용도
JPH07145129A (ja) β−ナフトキノン誘導体及びそれらの塩類の新規な用途
JPWO2017170860A1 (ja) ヒートショックプロテイン４７阻害剤
US20080287509A1 (en) Pharmaceutical Composition for the Treatment of Bone Fracture
JP2026503263A (ja) 腎線維症等の疾患の治療又は予防における化合物１の使用
HK40110140A (en) Use of small-molecule compound having naphthylamine structure
CN101918364A (zh) 用于治疗高蛋白尿的药物组合物及方法
WO2004094446A1 (ja) １４員環マクロライド化合物を利用した、血管平滑筋の増殖に起因する疾患治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120723

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130115